Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
7.22
+0.12 (1.69%)
Nov 26, 2025, 4:00 PM EST - Market closed
Armata Pharmaceuticals Revenue
Armata Pharmaceuticals had revenue of $1.16M in the quarter ending September 30, 2025, a decrease of -61.02%. This brings the company's revenue in the last twelve months to $5.05M, down -7.55% year-over-year. In the year 2024, Armata Pharmaceuticals had annual revenue of $5.17M with 14.24% growth.
Revenue (ttm)
$5.05M
Revenue Growth
-7.55%
P/S Ratio
51.71
Revenue / Employee
$84,233
Employees
60
Market Cap
262.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.17M | 645.00K | 14.24% |
| Dec 31, 2023 | 4.53M | -979.00K | -17.77% |
| Dec 31, 2022 | 5.51M | 1.03M | 23.11% |
| Dec 31, 2021 | 4.47M | 3.65M | 443.62% |
| Dec 31, 2020 | 823.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ARMP News
- 9 days ago - Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST - PRNewsWire
- 15 days ago - Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update - PRNewsWire
- 17 days ago - Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California - PRNewsWire
- 5 weeks ago - Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™ - PRNewsWire
- 6 weeks ago - Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™ - PRNewsWire
- 2 months ago - Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology - PRNewsWire
- 3 months ago - Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update - PRNewsWire